NCT06592352View on ClinicalTrials.gov

MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 27, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
Multiple SclerosisCognitive Impairment
Interventions
DRUG

Modafinil Generis 100 mg

All participants enrolled in the study will receive the study intervention drug (Modafinil Generis 100 mg). Dose 200 mg once per day (2 tablets of 100 mg) in the morning for 3 months (84 days), Oral administration

Trial Locations (1)

4710-243

RECRUITING

Clinical Academic Center - Braga (2CA-Braga), Braga

All Listed Sponsors
lead

Clinical Academic Center (2CA-Braga)

OTHER